Technology directory
A directory of all technologies currently available for licensing through UCLB.
- By Keyword(s)
- By Reference No.
There are 41 items in the directory (displaying results 1 to 20)
An ideal adhesive for bone repair : Injectable, Rapidly Crosslinkable, Biodegradable Poly(esters) Containing Reactive Calcium Phosphate Fillers
The major problem with current poly(methylmethacrylate) (PMMA) bone cements is their non degradability. Injectable calcium phosphate cements provide elements required for bone formation but are of low strength and have setting and degradation rates that are difficult to control. Greater control over setting and degradation is possible using short chain fluid crosslinkable polyesters end capped with methacrylate groups. These materials can also provide sustained release of a wide range of drugs but the acid degradation products of the polymer can cause inflammatory responses and the set materials have too low a modulus for bone (i.e. are too flexible).
| Reference: | 74-959 |
|---|---|
| Availability: | Available for exclusive/non-exclusive licensing |
Model Human skin: A Reproducible, High Throughput and Controllable Synthetic Skin Equivalent
A Novel solution for creating any type of human skin very rapidly (in a matter of minutes rather than weeks/months). The technology can produce identical tissue samples, which could find uses for testing skin products, skin grafts or even cornea generation.
| Reference: | 66-037 |
|---|---|
| Availability: | Licensing or Investment |
Novel Oncology Therapeutic: PKB/AKT Inhibitors
Phosphoinositide (PI) signalling is of utmost importance for cellular function and ultimately human health. Phosphoinositides are important regulators of many signal transduction processes. They control such critical processes as cell growth, communication and differentiation, the understanding of which will ultimately lead to treatments for human diseases such as diabetes or cancer. Phosphorylation and phosphate removal performed by various kinases and phosphatases, respectively, as well as the release of the inositol headgroup by phospholipases are the crucial players that control the flux of inositol lipid metabolism. In particular, the influence of PI 3-kinases for cellular signalling is well documented highlighting the importance of this enzyme in oncology and diabetes. Akt/PKB is a central component of the cell survival pathway and thus has been an important target for oncology drugs
| Reference: | 23-914 |
|---|---|
| Availability: | Further Exemplification – Potential Wellcome Trust Seeding Drug Discovery Award |
A Therapeutic Trial of an Alpha-1 Adrenoceptor Antagonist in Fatty Liver Disease
Non alcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver disease in developed countries. There is at present no proven therapy for NAFLD. The population prevalence of NAFLD is ~25% with the prevalence of its more severe stage, of fatty liver with inflammation, non alcoholic steatohepatitis (NASH) at ~2.5%. The main therapeutic targets in NASH are arguably fibrogenesis and liver regeneration because in NASH hepatic stellate cells (HSC) – the liver’s principal fibrogenic cells are activated to deposit collagen and other matrix proteins and also because in NASH hepatocyte replication is inhibited secondary to increased oxidant stress. This replicative arrest of hepatocytes in NASH therefore necessitates expansion of the liver’s stem cell compartment to maintain the functional integrity of the liver. An ideal therapy in NASH should therefore be both anti-fibrotic and also expand the liver stem cell compartment to enhance liver repair.
| Reference: | 60-034 |
|---|---|
| Availability: | Further Exemplification – Potential Wellcome Trust Translational Award |
The PSIPRED Protein Structure Prediction Server
The PSIPRED protein structure prediction server allows you to submit a protein sequence, perform a prediction of your choice and receive the results of the prediction via e-mail. You may select one of three prediction methods to apply to your sequence: PSIPRED - a highly accurate method for protein secondary structure prediction, MEMSAT - our widely used transmembrane topology prediction method and GenTHREADER - a sequence profile based fold recognition method.
| Reference: | 30-004 |
|---|---|
| Availability: | Non Exclusive Licensing |
A Surgical Kit for Hemiarthroplasty Hip/Shoulder Replacement or Refurbishment
The technology developed at UCL consists of a surgical kit that is suited for performing a hip hemiarthroplasty, in which a femoral head is fitted directly into a socket reamed into the acetabular without any permanent liner or prosthetic acetabular being implanted. This methodology will therefore alleviate the requirement for prosthetic acetebular replacement, and the associated problems of repeat surgery to implant a new prosthetic acetebular.
| Reference: | 66-021 |
|---|---|
| Availability: | Licensing |
A Revolutionary New Type of 2-Photon Microscope, that Focuses and Scans the Laser Beam in 3D Space
We have designed and built a prototype of a revolutionary new type of 2-photon microscope. Many important, yet poorly understood processes in biology, such as electrical signalling in neural circuits, are rapid and are distributed in 3D space. Such processes are impossible to monitor with conventional optical methods which are 100-fold too slow. Our new prototype laser scanner, can not only focus and scan the laser beam in 3D space, but offers a 300 fold increase to focusing time.
| Reference: | 41-006 |
|---|---|
| Availability: | Licensing |
The London Project to Cure Blindness: Stemming Vision Loss Using Stem Cells
The UCL Institute of Ophthalmology is leading a project to cure Age-Related Macular Degeneration (AMD) called the ‘’London Project to Cure Blindness’’. The aim of the project is to develop a surgical therapy to stabilise and restore vision in people who go blind due to faulty retinal pigment epithelial cells (RPE).
| Reference: | 88-035 |
|---|---|
| Availability: | Investment sought |
Method and Apparatus For Determining Effectiveness of Sunscreens and Other Skin Preparations In Shielding Human Skin From UVA Radiation
The invention, developed by Dr Rachel Haywood at RAFT, shows that even when sunscreen creams are applied in the correct dosage, the sun’s UVA light penetrates through to the skin and causes the release of free radicals. Dr Haywood demonstrated that three commonly available typical high SPF sunscreen creams (which indicated that they contained some UVA protection) have been applied to the skin in recommended doses and are seen NOT to protect sufficiently against the release of free radicals (Haywood R et al ).
| Reference: | 16-002 |
|---|---|
| Availability: | Exclusive/non-exclusive licensing |
Phenothiazine Derivatives: Treatment for Neurodegeneration
Lipid peroxidation resulting from oxidative stress is a crucial factor in the pathogenesis of many diseases, including neurodegenerative disorders, cardiovascular disease, asthma and diabetes. Phenothiazine derivatives are capable of reducing or preventing lipid peroxidation and therefore have potential therapeutic value for numerous disease states.
| Reference: | 92-009 |
|---|---|
| Availability: | Licensing and co-development |
Osteoporosis Diagnostic
This invention identifies variations at a gene which can predict whether or not a patient will respond to Bisphosphates. Approximately 40% of recipients do not respond to Bisphosphonate treatment. The identification of non-responding individuals holds the potential to facilitate patients receiving a more appropriate course of treatment. The total world market for osteoporosis drugs surpassed an estimated £6.35 billion in 2006, and we believe that the market for a predictive assay of this type is extremely large. It is our proposal that all patients about to start any oral Bisphosphates treatment for osteoporosis should be tested to demonstrate their ability to respond to the treatment regime.
| Reference: | 22-002 |
|---|---|
| Availability: | Exclusive/non-exclusive licensing |
Mutation Associated with the spread of Cancer
For most cancers, the spread of the disease beyond the primary site makes the difference between cure and failure. We have discovered a gene that is mutated at a very high frequency in prostate and breast cancer and appears to be associated with the spread of the disease
| Reference: | 69-006 |
|---|---|
| Availability: | Exclusive/non-exclusive licensing |
DDAH-Knockout Mice: Tool for Cardiovascular Disease Research
Dimethylarginine dimethylaminohydrolase 1 (DDAH1) -knockout mice are a useful tool for studying the effect of the accumulation of methylarginines (amino acids that regulate nitric oxide signalling in blood vessels) on vascular function, and for examining their potential role in cardiovascular disease.
| Reference: | 60-030 |
|---|---|
| Availability: | For material transfer by agreement |
Non-Immunogenic Protein Derived from Keratinous Substances
A UCL researcher has developed a novel process for extracting keratin which seems to be faster and simpler than existing protocols. He is currently doing some tests in cattle to confirm the biostability of the keratin extracted by his process and experimenting with other additives to improve the product.
| Reference: | 38-004 |
|---|---|
| Availability: | Co-development and exclusive/non-exclusive licensing |
SCN1A: A Genetic Predictor for the Use of Drugs for Epilepsy and Other Neurological Conditions
The dosing of two major anti-epileptic drugs (phenytoin and carbamazepine) is associated with a polymorphism in the sodium channel gene SCN1A. An exclusive or non-exclusive licence is available.
| Reference: | 31-001 |
|---|---|
| Availability: | Exclusive/non-exclusive licensing |
Novel Treatment for Crohn’s Disease
The invention relates to the use of pro-inflammatory agents such as interleukin 8 (IL-8) in a treatment for Crohn’s disease.
| Reference: | 60-079 |
|---|---|
| Availability: | Co-development and exclusive/non-exclusive licensing. |
Drug Lifecycle Visualisation Tool – In Vivo
Somatotrangenic bioimaging is a malleable platform technology for continued, quantifiable analysis of drug therapy, metabolism or toxicity in small animals.
| Reference: | 55-002 |
|---|---|
| Availability: | Licensing or investment |
Endomagnetics - SentiMAG™, for the Staging and Treatment of Breast Cancer
The SentiMAG™ is an ultrasensitive hand-held magnetic probe which can be used in conjunction with a magnetic dye to quickly and easily locate the sentinel lymph node for biopsy in breast cancer patients.
| Reference: | 26-001 |
|---|---|
| Availability: | Investment |
Novel UCL Nanocomposite Polymer and its Unique Role in the Field of Biomedical Devices
Our novel nanocomposite polymer (NC) can uniquely achieve complete tissue and blood compatibility, unlike conventional medical polymers such as PTFE and Dacron. This offers exciting possibilities for medical device manufacturers.
| Reference: | 94-092 |
|---|---|
| Availability: | Exclusive and non exclusive licensing opportunities |
Domainex Ltd: Solutions for Drug Discovery Problems
Domainex is a UK-based contract research company with breakthrough solutions for the major bottlenecks in drug discovery - the expression of challenging proteins or of their functional domains, and the design and synthesis of novel drug candidates. Domainex is applying its unique biology and chemistry services to its own internal drug discovery pipeline.
| Reference: | 39-928 |
|---|---|
| Availability: | Commercial contract research |
